Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2013

View Archived Issues

PDL BioPharma acquires royalty rights and milestones for type 2 diabetes products from Depomed

Researchers at Bristol-Myers Squibb present novel inhibitors of endothelial lipase

InnoCore and Allergan expand collaboration to develop new medicines for ophthalmic diseases

Boehringer Ingelheim describes new GPR40 receptor agonists

Isis Pharmaceuticals patents novel antisense oligonucleotides

Anacor receives award from Department of Defense for new classes of systemic antibiotics

Qiagen and Clovis partner to develop companion diagnostic for lung cancer candidate

MedMira receives further U.S. Army funding to develop tests for transfusion transmitted diseases

Merck & Co.'s combination regimen for chronic HCV obtains FDA breakthrough therapy designation

Russian company completes initial clinical trial steps for ABP-560

Taiho presents TAS-121, a potent and selective EGFR inhibitor

Gene therapy company Spark Therapeutics spun out of The Children's Hospital of Philadelphia

Antisense oligonucleotide ISIS-560131 targets the androgen receptor and reduces tumor growth in vivo

ERP29, IKBKAP gene polymorphisms associated with breast cancer risk and clinical features

Pharmacokinetics and pharmacodynamics determined for CW-002 in healthy volunteers

Mouse model created for genetic susceptibility to both dementia and Parkinson's disease

Daiichi Sankyo discloses new SGLT1/SGLT2 inhibitors

Merck & Co. and ElexoPharm prepare novel CYP11B2 inhibitors

New MCH1 receptor antagonists reported by GlaxoSmithKline

Sucampo and Takeda begin pivotal trial of lubiprostone liquid formulation

Roche recaps progress of third quarter 2013

ViiV Healthcare submits NDA for single-tablet HIV regimen

Enrollment complete in phase III trial of ZS-9 for treatment of hyperkalemia

DBV Technologies and INSERM form collaboration to develop Viaskin for refractory hemophilia A

Epirus and Orygen Biotecnologia sign collaboration agreement for biotechnology products in Brazil

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...